Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and the current price. Learn more about REPL stock here.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Washington County, Pa., is preparing to welcome teams and families from around the world as the 75th annual Pony League World Series returns to in the coming da ...

Crime Junkie aired new excerpts from purported Nancy Guthrie ransom notes, read by ex-reporter Briana Whitney. The unverified messages cite Bitcoin demands, crime scene details, and a second note ...

Baker Brothers’ Q1 2026 13F portfolio rose to $17.42B, with top five holdings—Incyte, BeOne Medicines, Insmed, Madrigal ...

Safari Technology Preview 248 delivers native BigInt Math as a JavaScript built-in for the first time, eliminating ...

Will Patterson crunches the numbers to see whether a viable alternative to Brobbey is currently available.

Arsenal are closing in on a deal to sign Christos Tzolis from Club Brugge, having reached an agreement to sign the winger for ...

The deal is the latest in a series of pacts that GE HealthCare has made with health systems, including Sutter Health and UC San Diego. Interoperability is a long term-challenge for the healthcare ...

Satellite images show China building a full-scale replica of a U.S. Navy destroyer in a remote desert. Thomas Shugart, a ...

The Uttar Pradesh government has sanctioned 1,155 permanent posts under the Special Security Force's 6th Battalion for the ...

The Pune-based IT firm has offered €81 per share in cash for Nagarro, at a 140% premium. As a combined group, they will have an expanded total Addressable Market (TAM) to over $1,400 billion, across ...